BR112015023351A2 - forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio - Google Patents

forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio

Info

Publication number
BR112015023351A2
BR112015023351A2 BR112015023351A BR112015023351A BR112015023351A2 BR 112015023351 A2 BR112015023351 A2 BR 112015023351A2 BR 112015023351 A BR112015023351 A BR 112015023351A BR 112015023351 A BR112015023351 A BR 112015023351A BR 112015023351 A2 BR112015023351 A2 BR 112015023351A2
Authority
BR
Brazil
Prior art keywords
sovaprevir
polymorph
shape
disorder
treating
Prior art date
Application number
BR112015023351A
Other languages
English (en)
Inventor
Phadke Avinash
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of BR112015023351A2 publication Critical patent/BR112015023351A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio a divulgação fornece formas cristalinas de sovaprevir. as formas cristalinas de sovaprevir compreendem um polimorfo de forma a, um polimorfo de forma b, um polimorfo de forma c, um polimorfo de forma d, e um polimorfo de forma e. os polimorfos de forma a, b, c, d e e exibem padrões de difração em pó de raios-x tendo localizações de picos em conformidade com as figuras 1, 4, 7, 10, e 13, respectivamente. 1/1
BR112015023351A 2013-03-15 2014-03-14 forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio BR112015023351A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361786927P 2013-03-15 2013-03-15
PCT/US2014/028348 WO2014144087A1 (en) 2013-03-15 2014-03-14 Sovaprevir polymorphs and methods of manufacture thereof

Publications (1)

Publication Number Publication Date
BR112015023351A2 true BR112015023351A2 (pt) 2017-07-18

Family

ID=50483591

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023351A BR112015023351A2 (pt) 2013-03-15 2014-03-14 forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio

Country Status (11)

Country Link
US (2) US9227952B2 (pt)
EP (1) EP2970192A1 (pt)
JP (1) JP2016513732A (pt)
KR (1) KR20160005686A (pt)
AU (1) AU2014227849A1 (pt)
BR (1) BR112015023351A2 (pt)
IL (1) IL241290A0 (pt)
MX (1) MX2015013020A (pt)
PH (1) PH12015502122A1 (pt)
SG (1) SG11201507467VA (pt)
WO (1) WO2014144087A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906619B2 (en) 2006-07-13 2011-03-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
GB201112231D0 (en) 2011-07-15 2011-08-31 Verdant Bioproducts Ltd Micro-organism
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69002950T2 (de) 1989-07-19 1994-01-20 Upjohn Co Peptide mit diaminoglycolen als übergangszustandmimik.
WO1993025574A1 (en) 1992-06-12 1993-12-23 Pfizer Inc. Inhibitors of angiotensin i chymase(s) including human heart chymase
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
CN100391967C (zh) 2000-11-20 2008-06-04 布里斯托尔-迈尔斯斯奎布公司 丙型肝炎三肽抑制剂
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
DE60336550D1 (de) 2002-05-20 2011-05-12 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
US20060199773A1 (en) 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
DE60324552D1 (en) 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US6869964B2 (en) 2002-05-20 2005-03-22 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis C virus inhibitors
KR100840715B1 (ko) 2002-05-28 2008-06-23 삼성전자주식회사 백 라이트 어셈블리 및 이를 갖는 액정 표시 장치
EP1408031A1 (en) 2002-10-09 2004-04-14 3 D Gene Pharma Pyrolidine derivatives useful in treatment of hepatitis C virus infection
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
CN1771050A (zh) 2003-02-07 2006-05-10 益安药业 丙型肝炎丝氨酸蛋白酶的大环抑制剂
EP1599496B1 (en) 2003-03-05 2010-11-03 Boehringer Ingelheim International GmbH Hepatitis c inhibitor peptide analogs
EP1629000B1 (en) 2003-04-16 2009-02-18 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
ES2297424T3 (es) 2003-05-21 2008-05-01 Boehringer Ingelheim International Gmbh Compuestos inhibidores de la hepatitis c.
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
WO2005007681A2 (en) 2003-07-18 2005-01-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CN1856502A (zh) 2003-09-22 2006-11-01 贝林格尔.英格海姆国际有限公司 抗c型肝炎病毒活性的巨环肽
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
PT1680137E (pt) 2003-10-14 2013-02-21 Hoffmann La Roche Ácidos carboxílicos macrocíclicos e acilsulfonamidas como inibidores da replicação do vhc
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
ES2336009T3 (es) 2004-01-30 2010-04-07 Medivir Ab Inhibidores de la ns-3 serina proteasa del vhc.
MXPA06010389A (es) 2004-03-15 2007-01-19 Boehringer Ingelheim Int Procedimiento para preparar dipeptidos macrociclicos los cuales son adecuados para el tratamiento de infecciones virales de hepatitis c.
EP1749007A2 (en) 2004-03-30 2007-02-07 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
PL382845A1 (pl) 2004-07-16 2008-01-21 Gilead Sciences, Inc. Związki przeciwwirusowe
ES2366478T3 (es) 2004-07-20 2011-10-20 Boehringer Ingelheim International Gmbh Análogos peptídicos inhibidores de la hepatitis c.
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
WO2006033878A1 (en) 2004-09-17 2006-03-30 Boehringer Ingelheim International, Gmbh Process for preparing macrocyclic hcv protease inhibitors
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK1863833T3 (da) 2005-03-08 2013-12-02 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af makrocykliske forbindelser
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ563361A (en) 2005-06-02 2011-02-25 Schering Corp HCV protease inhibitors in combination with food
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
CA2615921C (en) 2005-07-20 2011-09-13 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs with a quinoline or a thienopyridine moiety
EP2305697A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
JO2768B1 (en) 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
US7951773B2 (en) 2005-09-09 2011-05-31 Boehringer Ingelheim International Gmbh Ring-closing metathesis process for the preparation of macrocyclic peptides
JP2009511595A (ja) 2005-10-11 2009-03-19 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルスの複製を阻害する化合物および方法
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906619B2 (en) 2006-07-13 2011-03-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
EP1881002A1 (en) 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
EA200900969A1 (ru) 2007-01-08 2010-02-26 Феномикс Корпорейшн Макроциклические ингибиторы протеазы гепатита с
US20080207528A1 (en) 2007-02-01 2008-08-28 Syaulan Yang Hcv protease inhibitors
CA2746264C (en) 2008-12-10 2017-11-14 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
TW201329025A (zh) * 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
CN105358137A (zh) 2013-03-15 2016-02-24 艾其林医药公司 Sovaprevir片剂

Also Published As

Publication number Publication date
MX2015013020A (es) 2016-06-10
WO2014144087A1 (en) 2014-09-18
AU2014227849A1 (en) 2015-10-01
JP2016513732A (ja) 2016-05-16
US9540346B2 (en) 2017-01-10
US20140275163A1 (en) 2014-09-18
US20160176847A1 (en) 2016-06-23
EP2970192A1 (en) 2016-01-20
SG11201507467VA (en) 2015-10-29
US9227952B2 (en) 2016-01-05
KR20160005686A (ko) 2016-01-15
PH12015502122A1 (en) 2016-01-25
IL241290A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
PL3027600T3 (pl) 1,4-dwupodstawione pochodne pirydazyny i ich zastosowanie do leczenia stanów związanych z niedoborem smn
CY1120173T1 (el) Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης
GEP20197011B (en) Heteroaryl compounds for kinase inhibition
EA201691194A1 (ru) Стимуляторы ргц
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
AR090253A1 (es) Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
HK1219474A1 (zh) -氨基吡啶並 嘧啶- -酮衍生物及其作為 抑制劑的用途
JO3317B1 (ar) مركبات تترا هيدروبيرولو ثيازين
PE20141061A1 (es) Compuesto inhibidor de la senalizacion de la trayectoria notch
BR112015023184A2 (pt) método para o tratamento de uma doença, inibidor e seu uso, composição, método de identificação de um composto e método para inibir a produção de il-4, il-5 e il-13
AR103444A1 (es) Forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos
BR112015023351A2 (pt) forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio
HK1223923A1 (zh) 用於治療癌症的作為 突變體抑制劑的 -或 -二氨基嘧啶化合物
WO2014153495A9 (en) Novel stat3 inhibitors
BR112019023123A2 (pt) Artigo pultrudado, uso do artigo pultrudado, método para formar o artigo
MX2022013274A (es) Compuestos de triazolo-pirimidina fusionados que tienen aplicacion farmaceutica util.
AR101368A1 (es) Forma cristalina de sofosbuvir y proceso para su preparación
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
CL2014002908A1 (es) Método para la preparación de 2-(2,3-dimetilfenil)-1-propanal y sus usos.
BR112017009854A2 (pt) composto, uso de um composto, e, método para tratamento de leucemia.
FR3002854B1 (fr) Source d'energie implantable ultrafine.
ZA201504631B (en) Highly concentrated, water-free amine salts of hydrocarbon alkoxysulfates and use and method using aqueous dilutions of the same
MX2016002965A (es) Metodo para producir polvo hidraulico.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]